NASDAQ: XFORX4 Pharmaceuticals Inc Stock
$4.13+0.04 (+0.98%)
Updated Jul 2, 2026
XFOR Price
$4.13
Fair Value Price
$2.65
Market Cap
$389.54M
52 Week Low
$1.35
52 Week High
$4.83
P/E
-1.24x
P/B
2.31x
P/S
57.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.01M
Earnings
-$99.72M
Gross Margin
81.8%
Operating Margin
-1,008.5%
Profit Margin
-1,106.3%
Debt to Equity
0.61
Operating Cash Flow
-$93M
Beta
1.33
Next Earnings
Aug 14, 2026
Ex-Dividend
N/A
Next Dividend
N/A
XFOR Overview
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XFOR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
XFOR
Ranked#176 of 463
Ranked#176 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important XFOR news, forecast changes, insider trades & much more!
XFOR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XFOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XFOR ($4.13) is overvalued by 55.8% relative to our estimate of its Fair Value price of $2.65 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XFOR ($4.13) is not significantly undervalued (55.8%) relative to our estimate of its Fair Value price of $2.65 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XFOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XFOR due diligence checks available for Premium users.
Valuation
XFOR fair value
Fair Value of XFOR stock based on Discounted Cash Flow (DCF)
Price
$4.13
Fair Value
$2.65
Overvalued by
55.80%
XFOR ($4.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XFOR ($4.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XFOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XFOR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.24x
Industry
17.59x
Market
8.54x
XFOR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.31x
Industry
5.6x
XFOR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XFOR's financial health
Profit margin
Revenue
$2.7M
Net Income
-$20.2M
Profit Margin
-747.5%
XFOR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XFOR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$270.3M
Liabilities
$101.8M
Debt to equity
0.61
XFOR's short-term assets ($241.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XFOR's short-term assets ($241.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XFOR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XFOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.6M
Investing
$19.3M
Financing
$2.0k
XFOR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XFOR vs Biotech Stocks
X4 Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.